These Penny Stocks Are Reporting Key Data This Week
Looking for penny stocks to buy can be a task especially if there are many to choose from. When it comes to weekend research one of the main search topics involves potential catalysts. So you might say, “It’s the weekend, no one reports news.” This is true, however, some companies will update well in advance on key data readout dates. This can give you some insight into putting together a proper list of penny stocks to watch.
Read More
- How To Make Money No Matter Where The Market Goes – 5 Key Lessons
- Frequently Asked Questions About Low-Priced Equities
Similar to earnings results, these data readouts can be a coinflip. But if you’re right in choosing the best penny stocks to buy, then you’ll likely see the potential for big returns. No guarantees, however. So keep this in mind. Just because a company reports “good topline results” doesn’t mean it can immediately produce a jump in stock price. Some companies will report good data but there may be certain sticking points that might inhibit future progress. Make sure you keep this in mind heading into the final days of March.
In light of this, it doesn’t hurt to have a penny stocks watch list prepared “just in case” these companies come through with strong results. When it comes to different phase trials, it’s also a good idea to research the previous history. Is this the first time they’re reporting information or did they previously fail and are taking another shot at the same or similar phase?
SPECIAL REPORT: A Unique Opportunity For Small-Cap Gold Stocks Right Now
Best Penny Stocks To Buy [or avoid]: Clearside Biomedical
For our long-term readers, Clearside Biomedical (CLSD Stock Report) has been on a penny stocks watch list since late October. Around that time, CLSD stock traded around $0.86 and was just beginning to gain attention. Clearside had just announced that Bausch Health acquired the exclusive license to develop and sell XIPERE. Fast-forward to right now and shares are trading 102% higher and the company is expected to report results this week.
Regenxbio Inc (RGNX Stock Report) and Clearside could report two-year data from Cohorts 1-3 of the Phase 1/2a study of RGX-314 in wet age-related macular degeneration. This came up in Regenxbio’s financial highlights update in late-February. Last year, Regenxbio exercised its option to license Clearside’s in-office SCS Microinjector for delivering adeno-associated virus-based therapeutics. Its target is treating “wet age-related macular degeneration, diabetic retinopathy and other conditions”.
These results could impact Clearside so it will be something to take note of. Obviously, if everything is showing favorably, then CLSD stock could jump. On the flip side, a negative result or partial result could trigger a slide. So, if Clearside is on your list of penny stocks right now, I’d be on the look-out for updates related to this.
SPECIAL REPORT: A Unique Opportunity For Small-Cap Gold Stocks Right Now
Best Penny Stocks To Buy [or avoid]: AIM ImmunoTech
Next, AIM ImmunoTech (AIM Stock Report) has become a frequent name on penny stock watch lists this quarter. The rising excitement surrounding coronavirus penny stocks has also helped. Late last week the company announced that it’s seeking investigators and sites in its application of the lead product candidate, Ampligen, as a possible COVID-19 treatment.
“Since the first news of the outbreak, our focus and efforts have been devoted to developing Ampligen as an intranasal and oral protective prophylaxis and as an intravenous early-onset treatment for this highly pathogenic coronavirus.” – AIM CEO Thomas K. Equels.
However, in its 3rd quarter update last year, the company revealed something else that could be of interest right now. AIM reported that “In as early as the end of the first quarter of 2020, publication of data from a Phase 1/2 study of intraperitoneal chemo-immunotherapy in advanced recurrent ovarian cancer at University of Pittsburgh Medical Center,” could become available.
Since this week includes that last 2 days of Q1, 2020, it may be wise to keep this in mind. Long-before coronavirus became a buzzword, AIM was working on numerous immunotherapies. If the company reports data unrelated to coronavirus, will it be as impactful as some of the previous COVID-19 headlines?
SPECIAL REPORT: A Unique Opportunity For Small-Cap Gold Stocks Right Now
Best Penny Stocks To Buy [or avoid]: Sorrento Therapeutics Inc.
Another popular coronavirus penny stock right now, Sorrento Therapeutics In.c (SRNE Stock Report) is in a similar situation as AIM. It announced earlier this year that it expected initial data on early Phase readouts of its osteoarthritis treatment. However, a quick look at the latest string of headlines and you’ll see a major focus on coronavirus.
Prior to COVID-19, the company focused on cancer treatments and the external pain management of side-effects of certain cancers. However, with the advent of the coronavirus pandemic, it’s become full-steam ahead for Sorrento. In its last update, the company said it was in talks with the FDA to advance a COVID-19 cellular vaccine program to human testing.
Read More
- Looking For Penny Stocks To Buy? 3 Trading Higher This Week
- Are These Penny Stocks To Buy Or Sell Right Now?
- What Are The Best Penny Stocks? Some Names To Know
“We have developed a novel approach to vaccination that we believe can be a breakthrough in the fight against COVID-19. We believe using a human cell as a training agent is unique and likely to be effective for vaccination,” stated Dr. Henry Ji, Chairman, and CEO of Sorrento Therapeutics. Whether or not the results from its arthritis treatment are reported this week may not be as important to Sorrento. But, if SRNE is on your list of penny stocks this week, it may be worth keeping an eye out for that data.
SPECIAL REPORT: A Unique Opportunity For Small-Cap Gold Stocks Right Now
Penny Stocks To Buy [or avoid]: Ekso Bionics Holdings
Ekso Bionics Holdings (EKSO Stock Report) saw a wild end to the week last week. On the 24th it completed a 1 for 15 reverse stock split. Following the initial split, shares saw instant selling for roughly 2 sessions. But on Friday, EKSO stock rallied big into the close. The initial spark came around 3:15 PM EST and lasted right into the closing bell. So what could have been a potential catalyst behind the move?
Well, a look at the company’s newsfeed and filings doesn’t show much of anything in a related timeframe. But if you search for some related topics, Ekso Bionics starts to come up. Specifically, several industry reports were released over the last 3 days from multiple research companies. When it comes to the exoskeleton market and non-surgical robotics, Ekso comes up as one of the top companies. But there may be another line of thought on Ekso.
This is just an opinion on extreme speculation. However, if you look at anything related to coronavirus right now, nothing has been out of the question. Ekso has abilities to 3D print its exoskeletons. Right now, one of the hot-button items in the COVID-19 world is 3D printing. Specifically, 3D printing medical devices amid a global shortage. These are for things like testing and even active care.
While this could be a stretch, let’s not forget all of the immunotherapy companies that caught a surge earlier this year. That’s simply based on the ability for those companies to apply an immune treatment so a virus. In this case, coronavirus was the most current headline. Could that be the case for EKSO right now?
Penny Stocks To Buy [or avoid]: SuperCom Ltd
*Updated March 30, 2020; 7:00 AM EST* Last on the list, SuperCom Ltd (SPCB Stock Report) has jumped up big during Monday’s premarket session. As with many companies right now, SuperCom has reported coronavirus-related news. Believe it or not, the market is excited about a tech company and its move to “help” with coronavirus.
So what did SuperCom announce? The company said that it shipped equipment designated for an “urgent pilot” of its coronavirus citizen quarantine compliance technology. Is this a bit of a stretch? You decide. Essentially, the company shipped out ankle monitors and “smartphones” to keep tabs on “low-risk” a high-risk cases. I’m all for helping to flatten the curve but tracking is bordering on a different line.
Needless to say, it’s COVID-19 news so why wouldn’t the market get excited. Shares of SPCB stock jumped to highs of $1.25 before the opening bell. What will be important to watch is how the stock actually opens. We’ve seen a lot of big movers during premarket hours but as soon as the market opens, it can sell-off. So if SPCB is on you list of penny stocks, keep this in mind.
